Has Veronica Dugan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $16,731 in general payments to Veronica Dugan, MD across 1,136 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Veronica Dugan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Veronica Dugan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Veronica Dugan, MD

Gastroenterology · Slidell, LANPI 1245292515

Payments from drug & device makers

$16,731in general payments, 2019–2025

Across 1,136 payments — averaging $14.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$5K
Takeda Pharmaceuticals U.S.A., Inc.$2K
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
Gilead$1K
Johnson & Johnson$1K
Bristol Myers Squibb$842
plus $5K from 40 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	367	$4,935
Takeda Pharmaceuticals U.S.A., Inc.	140	$1,790
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	123	$1,495
Gilead	62	$1,452
Johnson & Johnson(2 entities)	99	$1,426
Bristol Myers Squibb	54	$842
Pfizer	58	$761
Merck	25	$401
QOL Medical, LLC	22	$385
Daiichi Sankyo Inc.	13	$284
Intercept Pharmaceuticals, Inc.	18	$260
Lilly USA, LLC	14	$215
Boston Scientific	6	$212
Celltrion USA Inc.	12	$210
Sanofi	9	$196
Shionogi Inc	9	$150
Ardelyx, Inc.	7	$142
Regeneron Healthcare Solutions, Inc.	6	$140
UCB, Inc.	9	$135
Phathom Pharmaceuticals, Inc.	9	$112
Ironwood Pharmaceuticals, Inc	7	$107
Romark Laboratories, LC	8	$105
Ipsen Biopharmaceuticals, Inc	5	$99
Amgen	4	$83
Redhill Biopharma Inc.	5	$82
Micro-tech Endoscopy USA, Inc.	2	$76
Braintree Laboratories, Inc.	6	$76
Nestle Healthcare Nutrition Inc.	4	$75
Pharmacosmos Therapeutics Inc.	4	$70
Evoke Pharma, Inc.	3	$53
Organon	4	$46
Shire North American Group Inc	3	$41
Pentax Of America, Inc.	1	$40
Axonics, Inc.	2	$35
Biocon Biologics Inc	2	$33
Madrigal Pharmaceuticals	1	$25
Aimmune Therapeutics, Inc.	1	$21
Alfasigma USA, Inc.	1	$20
Intra-sana Laboratories	1	$17
Ferring Pharmaceuticals Inc.	1	$17
Steris Corporation	1	$17
Fresenius Kabi USA, LLC	1	$14
Medtronic	1	$14
Endo Pharmaceuticals Inc.	1	$14
Echosens North America, Inc.	1	$11
Gastrogpo, LLC	4	$0

How this compares

$16,731 in reported general payments places this provider in the 75th percentile of 254 gastroenterology providers in Louisiana.

See all gastroenterology providers in Louisiana →

Medicare billing

Part B allowed, 2024

$300,151

Medicare patients

421

Services billed

9,181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Payments from drug & device makers

Who reported the general payments

How this compares

Medicare billing

Other gastroenterology in Slidell